Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients

Authors: Rein Jan Piso, Madeleine Rothen, Jean Pierre Rothen, Matthias Stahl, Christoph Fux

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Osteoporosis and bone fractures seem to be higher in HIV-infected Patients compared to the general populations. Moreover, bone turnover markers are increased in patients on antiretroviral therapy and vitamin D deficiency is prevalent in HIV-infected patients. However, the influence of per oral cholecalciferol on bone metabolism in HIV infected patients is not well understood.

Methods

We measured the bone turnover markers in 96 HIV-infected patients: Bone specific alkaline phosphatase (BSAP), Pyridinoline (PYR), Desoxypyridinoline (DPD) and 25-OH vitamin D. If 25-OH vitamin D was below 75 nnol/L (87/96 patients), 300000 IU cholecalciferol was given per os. 25OH-vitamin D and bone turn over markers were determinded 3 month later. 25 OH-vitamin D was corrected for circannual rythm y ' = y + 17.875 * sin 2 π 365 * day + 2.06 , whereas bone turnover markers were not corrected. The paired students t-Test was used to compare the two periods. No calcium supplementation or biphosphonate therapy was given.

Results

Corrected 25OH-vitamin D levels increased significantly after supplementation (42.7 ± 26.61 vs. 52.85 ± 21.8 nmol/L, p < 0.001). After supplementation, bone turnover markers were significantly lower. The values decreased for BSAP from 21.31 ± 14.32 to 17.53 ± 8.17 μg/L (p < 0.001), PYR from 74.57 ± 36.83 to 54.82 ± 21.43 nmol/mmol creatinine (p < 0.001) and DPD from 15.17 ± 8.34 to 12.61 ± 5.02 nmol/mmol creatinine (p = 0.01).

Conclusions

After per oral substitution with cholecalciferol, bone formation as well as bone resorption markers decreased significant. We postulate a protective effect on bone structure with cholecalciferol supplementation.
Appendix
Available only for authorised users
Literature
1.
Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A: Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013, 177 (2): 116-125. 10.1093/aje/kws321.CrossRefPubMedPubMedCentral
2.
Castronuovo D, Cacopardo B, Pinzone MR, Di Rosa M, Martellotta F, Schioppa O, Moreno S, Nunnari G: Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci. 2013, 17 (18): 2413-2419.PubMed
3.
Young B, Dao CN, Buchacz K, Baker R, Brooks JT, HIV Outpatient Study (HOPS) Investigators: Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011, 52 (8): 1061-1068. 10.1093/cid/ciq242.CrossRefPubMed
4.
Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, Bush T, Brooks JT, Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Investigators: Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011, 52 (3): 396-405. 10.1093/cid/ciq158.CrossRefPubMed
5.
Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, Magenta L, Calmy A, Vergopoulos A, Bischoff-Ferrari HA, the Swiss HIV Cohort Study: High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010, 24 (8): 1127-1134. 10.1097/QAD.0b013e328337b161.CrossRefPubMed
6.
Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A: Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009, 200 (11): 1746-1754. 10.1086/644785.CrossRefPubMed
7.
Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercie P, Morlat P, Thiebaut R, Dabis F, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine: Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008, 22 (3): 395-402. 10.1097/QAD.0b013e3282f423dd.CrossRefPubMed
8.
Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, Post FA: Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010, 24 (12): 1923-1928. 10.1097/QAD.0b013e32833c3281.CrossRefPubMed
9.
Piso RJ, Rothen M, Rothen JP, Stahl M: Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011, 56 (4): 320-324. 10.1097/QAI.0b013e31820cf010.CrossRefPubMed
10.
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group: Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010, 51 (8): 963-972. 10.1086/656417.CrossRefPubMed
11.
Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009, 51 (5): 554-561. 10.1097/QAI.0b013e3181adce44.CrossRefPubMed
12.
Woitge HW, Knothe A, Witte K, Schmidt-Gayk H, Ziegler R, Lemmer B, Seibel MJ: Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res. 2000, 15 (12): 2443-2450. 10.1359/jbmr.2000.15.12.2443.CrossRefPubMed
13.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96 (7): 1911-1930. 10.1210/jc.2011-0385.CrossRefPubMed
14.
Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trikalinos TA: Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep). 2009, 183 (183): 1-420.
15.
Zhu K, Devine A, Dick IM, Wilson SG, Prince RL: Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab. 2008, 93 (3): 743-749.CrossRefPubMed
16.
Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC: Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int. 2012, 91 (6): 423-429. 10.1007/s00223-012-9653-y.CrossRefPubMed
17.
Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J: Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005, 11 (12): 1843-1847.CrossRefPubMedPubMedCentral
18.
Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M: Association between vitamin D and hepatitis C virus infection: A meta-analysis. World J Gastroenterol. 2013, 19 (35): 5917-5924. 10.3748/wjg.v19.i35.5917.CrossRefPubMedPubMedCentral
19.
Kong J, Ding Y, Zhang C, Fu Y, Du J, Lu C, Dou X, Chen Y, Li YC, Zhao Q: Severe vitamin D-deficiency and increased bone turnover in patients with hepatitis B from northeastern China. Endocr Res. 2013, 38 (4): 215-222. 10.3109/07435800.2013.768266.CrossRefPubMed
20.
Petta S, Ferraro D, Camma C, Cabibi D, Di Cristina A, Di Marco V, Di Stefano R, Grimaudo S, Mazzola A, Levrero M, Scazzone C, Craxi A: Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther. 2012, 17 (5): 823-831. 10.3851/IMP2100.CrossRefPubMed
21.
Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR: The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007, 86 (4): 959-964.PubMed
22.
Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, Cohen MH, Justman J, Hessol NA: The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007, 12 (7): 1049-1058.PubMed
23.
Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Foca E, Ceccarelli G, D'Ettorre G, Vullo V, Fisichella R, Cacopardo B, Nunnari G: Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013, 17 (9): 1218-1232.PubMed
24.
Rossini M, Adami S, Viapiana O, Fracassi E, Idolazzi L, Povino MR, Gatti D: Dose-dependent short-term effects of single high doses of oral vitamin d(3) on bone turnover markers. Calcif Tissue Int. 2012, 91 (6): 365-369. 10.1007/s00223-012-9637-y.CrossRefPubMed
25.
Etminani-Esfahani M, Khalili H, Jafari S, Abdollahi A, Dashti-Khavidaki S: Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes. 2012, 5 (1): 204-10.1186/1756-0500-5-204.CrossRefPubMedPubMedCentral
26.
Bang UC, Kolte L, Hitz M, Schierbeck LL, Nielsen SD, Benfield T, Jensen JE: The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial. AIDS Res Hum Retroviruses. 2013, 29 (4): 658-664. 10.1089/aid.2012.0263.CrossRefPubMed
27.
Herrmann W, Kirsch SH, Kruse V, Eckert R, Graber S, Geisel J, Obeid R: One year B and D vitamins supplementation improves metabolic bone markers. Clin Chem Lab Med. 2012, 51 (3): 639-647.
28.
Lieben L, Carmeliet G: Vitamin D signaling in osteocytes: Effects on bone and mineral homeostasis. Bone. 2012, 54 (2): 237-243.CrossRefPubMed
29.
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007, 370 (9588): 657-666. 10.1016/S0140-6736(07)61342-7.CrossRefPubMed
30.
Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J: Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009, 169 (6): 551-561. 10.1001/archinternmed.2008.600.CrossRefPubMed
31.
Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B: Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004, 116 (9): 634-639. 10.1016/j.amjmed.2003.12.029.CrossRefPubMed
32.
Childs K, Kadish C, Branch-Elliman W, Fishman S, Mullen M, Branch A: Vitamin D can calcium supplements reverse the secondary hyperparathyroidism tha commonly ocurs. HIV Med. 2009, 10 (Suppl.1): 36-37.
33.
Havens P, Hazra R, Stephensen C, van Loan M, Rutledge B, Bethel J, et al: Vitamin D3 Supplementation Decreases PTH in HIV-infekcted Youth Being TReated wth TDF-containing Combination ART: A Randomized, Double-blind, Pacebo-controlled Multicenter Trial: Adult network Study 063 [abstract]. 18th Conference ib Retroviruses and Opportunistic Infections. 2011, Boston, MA,USA, Abstract 80
34.
Jacobson DL, Spiegelman D, Knox TK, Wilson IB: Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008, 49 (3): 298-308. 10.1097/QAI.0b013e3181893e8e.CrossRefPubMedPubMedCentral
35.
Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, Levine A, Cohen MH, Shane E, Golub ET, Tien PC: Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS. 2010, 24 (17): 2679-2686. 10.1097/QAD.0b013e32833f6294.CrossRefPubMedPubMedCentral
36.
Van Den Bout-van Den Beukel CJ, Van Den Bos M, Oyen WJ, Hermus AR, Sweep FC, Tack CJ, Bosch ME, Burger DM, Koopmans PP, Van Der Ven AJ: The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med. 2008, 9 (9): 771-779. 10.1111/j.1468-1293.2008.00630.x.CrossRefPubMed
37.
Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, Bollerslev J, Froland SS: Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999, 84 (1): 145-150. 10.1210/jc.84.1.145.PubMed
38.
Zabihiyeganeh M, Jahed A, Nojomi M: Treatment of hypovitaminosis D with pharmacologic doses of Cholecalciferol, Oral versus Intramuscular; an open labeled RCT. Clin Endocrinol (Oxf). 2012, 78 (2): 210-216.CrossRef
39.
Hackman KL, Gagnon C, Briscoe RK, Lam S, Anpalahan M, Ebeling PR: Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust. 2010, 192 (12): 686-689.PubMed
40.
Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis. 2005, 20 (3): 187-192. 10.1159/000087203.CrossRefPubMed
41.
Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010, 303 (18): 1815-1822. 10.1001/jama.2010.594.CrossRefPubMed
42.
Misselwitz J, Hesse V: Hypercalcemia following prophylactic vitamin D administration. Kinderarztl Prax. 1986, 54 (8): 431-438.PubMed
43.
Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M: Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011, 365 (5): 410-421. 10.1056/NEJMoa1103864.CrossRefPubMed
44.
Hoy J: Bone, fracture and frailty. Curr Opin HIV AIDS. 2011, 6 (4): 309-314. 10.1097/COH.0b013e3283478741.CrossRefPubMed
45.
Giacomet V, Vigano A, Manfredini V, Cerini C, Bedogni G, Mora S, Borelli M, Trabattoni D, Zuccotti GV: Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013, 14 (2): 51-60. 10.1310/hct1402-51.CrossRefPubMed
46.
Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, Labbato DE, Storer N, Tangpricha V, McComsey GA: Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012, 17 (4): 613-621.CrossRefPubMed
47.
Barnes MS, Robson PJ, Bonham MP, Strain JJ, Wallace JM: Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults. Eur J Clin Nutr. 2006, 60 (6): 727-733. 10.1038/sj.ejcn.1602374.CrossRefPubMed
48.
Lips P, van Schoor NM: The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011, 25 (4): 585-591. 10.1016/j.beem.2011.05.002.CrossRefPubMed
49.
Prestwood KM, Pannullo AM, Kenny AM, Pilbeam CC, Raisz LG: The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int. 1996, 6 (4): 314-319. 10.1007/BF01623391.CrossRefPubMed
50.
Robbins JA, Schott AM, Garnero P, Delmas PD, Hans D, Meunier PJ: Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int. 2005, 16 (2): 149-154. 10.1007/s00198-004-1661-y.CrossRefPubMed
Metadata
Title
Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients
Authors
Rein Jan Piso
Madeleine Rothen
Jean Pierre Rothen
Matthias Stahl
Christoph Fux
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-577

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue

Research article

The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study

Research article

Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study

Research article

An in vitro model of Mycobacterium lepraeinduced granuloma formation

Research article

Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?

Research article

Inflammatory parameters and prediction of prognosis in infective endocarditis

Research article

Trafficking of phagocytic peritoneal cells in hypoinsulinemic-hyperglycemic mice with systemic candidiasis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits